Press Releases

In a talk to be presented online as part of the American Association for Cancer Research (AACR) Virtual Annual Meeting II, Fumito Ito, MD, PhD, FACS, of Roswell Park Comprehensive Cancer Center will highlight new evidence that a biomarker for predicting response to checkpoint inhibitors in patients with lung cancer exists and can be detected through a blood test

The Ride for Roswell, presented by the West Herr Automotive Group, is excited to announce the locations and details for its in-person, scheduled, physically distant rides that are the features of this year’s Summer of the Ride. There will be four locations with five distances on six days this August.

Elected by a body of fellow immunotherapy researchers from across the globe, Roswell Park Comprehensive Cancer Center Deputy Director Kunle Odunsi, MD, PhD, FRCOG, FACOG, has been named an At-Large Director for the Society for Immunotherapy of Cancer (SITC) Board of Directors. The nonprofit organization’s members voted for Dr. Odunsi during their election in May. He will begin his three-year term in January 2021.

Roswell Park Comprehensive Cancer Center staff and patients are mourning a devastating loss. Oscar Colegio, MD, PhD, the Lawrence P. & Joan Castellani Family Endowed Chair in Dermatology at the Buffalo-based cancer center, died unexpectedly this weekend at a family residence in Connecticut.

New preclinical work by a team of researchers from Roswell Park Comprehensive Cancer Center’s Transplant and Cellular Therapy Program suggests that the risk of developing acute graft vs. host disease (GVHD) during allogeneic blood/marrow transplant (BMT) — a potentially curative treatment for selected patients with hematologic disorders — can be decreased using an existing class of drugs called beta adrenergic agonists.

Whether it is pioneering lab research or developing new procedures and treatments, innovation thrives at Roswell Park Comprehensive Cancer Center. Department of Urology surgeon Eric Kauffman, MD, was recognized for his novel approach for prostate cancer surgery by the American Urological Association (AUA), receiving a Best Video award for 2020.

Infusions of chemotherapy or other medications: They’re facets of oncology that often make up a big portion of a patient’s cancer care. It’s treatment that can take up many hours in a clinic or in an inpatient setting, delivered by dedicated oncology nurses and physicians. At Roswell Park Comprehensive Cancer Center, that dedication is seen day in and day out by veteran staff member Eunice Wang, MD, who has been selected to lead this team as the newly appointed Medical Director of Infusion Services.

In a study to be presented at the ASCO 2020 virtual meeting, a Roswell Park team reports that in many cases, targeted and immunotherapeutic approaches may reduce the risk of therapy-related myelodysplastic syndrome or acute myeloid leukemia (tMDS/AML) compared to chemotherapy-based treatment strategies.

Clinical oncology pathways are an important tool, helping cancer care providers and their patients to zero in on the most appropriate care plan. But a treating professional’s decision to depart from the recommendations of these decision-support resources may be well-founded and in the patient’s best interests, research being presented at the American Society of Clinical Oncology (ASCO) 2020 virtual meeting shows.